Invitae is a genetic testing company specializing in next-generation sequencing (NGS) services for clinical diagnostics, focusing on hereditary cancers, cardiovascular diseases, rare diseases, neurology, pediatrics, and women's health.[1][3][6] It serves patients, clinicians, and biopharma partners by offering multi-gene panels, exome sequencing, and supplementary RNA analysis, often at reduced costs through sponsored programs and flexible billing, with integration into Labcorp's network for broader accessibility.[3][4] The company solves the problem of high-cost, fragmented genetic testing by aggregating hundreds of genes into single, affordable assays and providing tools like patient identification, clinical trial recruitment, and genotype-phenotype data insights, having served over 5 million patients.[1][2][3]
Invitae's growth includes strategic partnerships with biopharma firms like Alnylam and Horizon Therapeutics for free rare disease testing, and an acquisition of AI-driven Jungla in 2019 to enhance variant interpretation.[1][2] Now part of Labcorp, it leverages nationwide infrastructure and in-network status with most U.S. health plans, emphasizing machine learning via Invitae Generation™ for definitive results and reducing variants of uncertain significance (VUS).[3][4][6]
Invitae was founded in 2010 as a spin-off from Genomic Health, aiming to democratize genetic testing by developing NGS-based services for the clinical market at lower costs than single-gene tests.[1] The idea emerged from the need to consolidate fragmented genetic assays into comprehensive panels covering over 600 genes for conditions like hereditary cancers, cardiovascular, neuromuscular, and rare diseases.[1] Early traction came from expanding offerings in oncology (e.g., panels for prostate, colorectal, breast cancers) and rare diseases, bolstered by sponsored testing with pharma partners such as Spark Therapeutics and X4 Pharmaceuticals.[1][2]
Pivotal moments include the 2019 acquisition of Jungla, an AI-biotech firm, which advanced variant interpretation for cancer and other applications, and its integration with Labcorp, enhancing scale, coverage, and patient access through Labcorp's network.[1][3][4]
Invitae rides the precision medicine wave, where NGS and AI enable personalized healthcare by linking genetics to disease risk, treatment response, and drug development.[1][2][6] Timing aligns with falling sequencing costs and rising demand for hereditary risk screening amid aging populations and cancer prevalence, amplified by post-pandemic telehealth integration.[3][4] Market forces like biopharma's need for real-world genetic cohorts (e.g., rare diseases underrepresented in general studies) favor Invitae, as do regulatory pushes for accessible diagnostics.[2]
It influences the ecosystem by accelerating clinical trials, validating therapies via natural history studies, and providing de-identified data for research, bridging diagnostics with pharma innovation—exemplified by partnerships yielding deeper genetic insights for firms like BridgeBio.[2]
Invitae's Labcorp integration positions it for scaled growth in routine genetic screening, potentially expanding into proactive wellness testing as AI refines variant calls and data volumes grow.[3][4][6] Trends like multi-omics integration, global trial recruitment, and payer-covered exome sequencing will shape its path, with biopharma demand for clinicogenomics driving revenue. Influence may evolve toward ecosystem orchestrator, powering AI-driven drug discovery and population health, fulfilling its founding vision of affordable, aggregated genetic insights for all.[1][2]
Invitae has raised $164.0M in total across 3 funding rounds.
Invitae's investors include Acorn Bioventures, Aisling Capital, HealthQuest Capital, Hercules Capital, Casey Tansey, J.P. Morgan Chase & Co..
Invitae has raised $164.0M across 3 funding rounds. Most recently, it raised $120.0M Series F in October 2014.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2014 | $120.0M Series F | Acorn Bioventures, Aisling Capital, HealthQuest Capital, Hercules Capital, Casey Tansey | |
| Dec 1, 2013 | $40.0M Series E | HealthQuest Capital | |
| Sep 1, 2010 | $4.0M Venture Round | J.P. Morgan Chase & Co. |
